[A current problem for regulators. Clopidogrel and pharmacokinetics]

Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326.

[Article in German]

Authors

Ilse Zündorf¹, Theo Dingermann

Affiliation

¹ Johann Wolfgang Goethe-Universität Frankfurt, Institut für Pharmazeutische Biologie, Max-von-Laue-Str. 9, 60438 Frankfurt. zuendorf@em.uni-frankfurt.de

PMID: 19572363
DOI: 10.1002/pauz.200900326

No abstract available

Publication types

Review

MeSH terms

Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
Aryl Hydrocarbon Hydroxylases / biosynthesis
Aryl Hydrocarbon Hydroxylases / genetics
Aryl Hydrocarbon Hydroxylases / metabolism
Clopidogrel
Cytochrome P-450 CYP2C19
Drug Industry
Drug Interactions
Drug Therapy, Combination
Enzyme Induction / drug effects
Enzyme Inhibitors / pharmacology
Humans
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / pharmacokinetics*
Platelet Aggregation Inhibitors / therapeutic use
Polymorphism, Genetic
Thrombosis / genetics
Thrombosis / prevention & control
Ticlopidine / adverse effects
Ticlopidine / analogs & derivatives*
Ticlopidine / pharmacokinetics
Ticlopidine / therapeutic use
United States
United States Food and Drug Administration

Substances

Enzyme Inhibitors
Platelet Aggregation Inhibitors
Clopidogrel
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Ticlopidine